Patient Gateway

RSS Feed

ALK-fusion-positive non-small cell lung cancer concomitant with 5q deletion myelodysplastic syndrome: a case report

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with iruplinalkib resistance

Strategies for Overcoming ALK TKI-resistance in ALK-fusion NSCLC

Reports Summarize Multikinase Inhibitors Findings from Center for Respiratory Diseases (Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre)

ALK- and ROS1-Positive NSCLC: Emerging Treatment Options

Opportunity to Join David Mosko for a Focused Update on ALK and ROS1 Aberrations - IHCI

Acquired EML4-ALK fusion and BRAF V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with lorlatinib: a case report

Opportunity to Join David Mosko for a Focused Update on ALK and ROS1 Aberrations – IHCI

Chemotherapy remains effective in ALK-TKI therapy: a retrospective analysis in ALK-positive advanced NSCLC

Treatment Selection for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.